Abstract 5078: FGFR2 gene amplification status in gastric carcinoma and clinicopathologic significance

Abstract

Abstract Background: Fibroblast growth factor receptor 2 (FRFG2) is a member of FGFR receptor tyrosine kinase family. FGFR2 gene amplification or missense mutation has been observed in various human cancers, including gastric carcinoma. Recent studies showed that, anti FGFR2 agents inhibit tumor progression in other tumors. Gastric carcinoma is one of the most frequent causes of cancer-related death worldwide. Evaluate the status of FGFR2 gene amplification in gastric carcinoma is beneficial in targeted cancer therapy. Methods: We evaluated FGFR2 amplification status in the surgically resected 312 gastric carcinoma cases, using fluorescence in situ hybridization (FISH) and real-time quantitative-polymerase chain reaction (q-PCR), and compared the results. We compared clinicopathologic parameters with the presence of FGFR2 amplification, and performed survival analysis. Results: Among 312cases, 14 cases (4.5%) showed FGFR2 amplification by FISH. FGFR2 amplification was associated to higher pT stage (p=0.015), pN stage (p=0.031) and distant metastasis (p=0.023). In survival analysis, FGFR2 amplification was significantly associated with lower cancer-specific survival in univariate analysis (p=0.012). The Real-time q-PCR results were concord with the FISH result. Conclusions: Gastric carcinoma with FGFR2 amplification showed more advanced disease and poor survival. Evaluate the FGFR2 amplification status may identify a subset of cancers that are sensitive to targeted therapy using FGFR2 inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5078.